Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases

Dermatology and Therapy

Volumn 3, Issue 1, 2013, Pages 1-15

  Wittmann, Miriam ^a,b,c   Helliwell, Philip S ^a,c  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c From the Bradford Hospitals Trust   (United Kingdom)

Author keywords

Apremilast; Chronic inflammatory disease; Dermatology; Phosphodiesterase inhibition; Psoriasis; Psoriatic arthritis; Treatment

Indexed keywords

AN 2728; APREMILAST; CYCLIC AMP; GLUCOCORTICOID; LIVER ENZYME; METHOTREXATE; PENTOXIFYLLINE; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; REACTIVE OXYGEN METABOLITE; ROFLUMILAST; THEOPHYLLINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ASTHMA; ATOPIC DERMATITIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CONTACT DERMATITIS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ECZEMA; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GRANULOMATOUS SKIN DISEASE; HAIR LOSS; HEADACHE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LIVER TOXICITY; LUNG SARCOIDOSIS; MELKERSSON ROSENTHAL SYNDROME; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SKIN ALLERGY; SKIN LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING;

EID: 84896142349     PISSN: None     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-013-0023-0     Document Type: Review

References (79)

1. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90.
2. Cassel D, Pfeuffer T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci USA. 1978;75:2669-73.
3. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185:6413-9.
4. Jeyaraj SC, Unger NT, Eid AH, Mitra S, Paul El-Dahdah N, Quilliam LA, Flavahan NA, Chotani MA. Cyclic AMP-Rap1A signaling activates RhoA to induce a(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells. Am J Physiol Cell Physiol. 2012;303:C499-511.
5. Zieba BJ, Artamonov MV, Jin L, et al. The cAMPresponsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity. J Biol Chem. 2011;286:16681-92.
6. Stokman G, Qin Y, Genieser HG, et al. Epac-Rap signaling reduces cellular stress and ischemiainduced kidney failure. J Am Soc Nephrol. 2011;22:859-72.
7. Kim JG, Moon MY, Kim HJ, et al. Ras-related GTPases Rap1 and RhoA collectively induce the phagocytosis of serum-opsonized zymosan particles in macrophages. J Biol Chem. 2012;287:5145-55.
8. la Sala A, He J, Laricchia-Robbio L, et al. Cholera toxin inhibits IL-12 production and CD8alpha? dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J Exp Med. 2009; 206:1227-35.
9. Coccia EM, Remoli ME, Di Giacinto C, et al. Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease. Gut. 2005;54:1558-64.
10. Lavelle EC, Jarnicki A, McNeela E, et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol. 2004;75:756-63.
11. BurkartV, Kim YE, Hartmann B, et al. Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. J Immunol. 2002;168:1730-7.
12. Boirivant M, Fuss IJ, Ferroni L, De Pascale M, Strober W. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol. 2001;166:3522-32.
13. Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur J Immunol. 2001;31:64-71.
14. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med. 1999;189:541-52.
15. Gschwandtner M, Bunk H, Köther B, et al. Histamine down-regulates IL-27 production in antigenpresenting cells. J Leukoc Biol. 2012;92:21-9.
16. Gutzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol. 2005;174:5224-32.
17. Caron G, Delneste Y, Roelandts E, et al. Histamine polarizes human dendritic cells into Th2 cellpromoting effector dendritic cells. J Immunol. 2001;167:3682-6.
18. van der Pouw Kraan TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998;102:1866-73.
19. Elenkov IJ, Webster E, Papanicolaou DA, et al. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol. 1998;161:2586-93.
20. Wu CY, Wang K, McDyer JF, Seder RA. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol. 1998;161:2723-30.
21. Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204:1303-10.
22. Klein M, Vaeth M, Scheel T, et al. Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol. 2012;188:1091-7.
23. Bodor J, Bopp T, Vaeth M, et al. Cyclic AMP underpins suppression by regulatory T cells. Eur J Immunol. 2012;42:1375-84.
24. Bodor J, Habener JF. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. J Biol Chem. 1998;273:9544-51.
25. Gerlo S, Kooijman R, Beck IM, et al. Cyclic AMP: a selective modulator of NF-kappaB action. Cell Mol Life Sci. 2011;68:3823-41.
26. Baumer W, Kietzmann M. Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes. Vet Dermatol. 2007;18: 107-14.
27. Qi XF, Kim DH, Yoon YS, et al. The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes. Mol Immunol. 2009;46:1925-34.
28. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157:351-70.
29. Jin SL, Ding SL, Lin SC. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J. 2012;35:197-210.
30. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275-86.
31. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297:267-79.
32. Smith SJ, Brookes-Fazakerley S, Donnelly LE, et al. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L279-89.
33. Milara J, Navarro A, Almudéver P, Lluch J, Morcillo EJ, Cortijo J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011;41:535-46.
34. Seybold J, Newton R, Wright L, et al. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. J Biol Chem. 1998;273:20575-88.
35. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4? T cells: predominant role of PDE4D. J Immunol. 2007;178:4820-31.
36. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol. 1999;55:50-7.
37. Magela Magalhaes G, Coelho da Silva Carneiro S, Peisinodo Amaral K, et al. Psoriasis and pentoxifylline: a clinical, histopathologic, and immunohistochemical evaluation. Skinmed. 2006; 5:278-84.
38. Singh SK, Dimri U, Saxena SK, Jadhav RK. Therapeutic management of canine atopic dermatitis by combination of pentoxifylline and PUFAs. J Vet Pharmacol Ther. 2010;33:495-8.
39. Park MK, Fontana Jr, Babaali H, et al. Steroidsparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:121-31.
40. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol. 2006;117: 1237-43.
41. Spina D, Landells LJ, Page CP. The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy. 1998;28:24-34.
42. Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:1045-52.
43. Kagayama K, Morimoto T, Nagata S, et al. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors. Bioorg Med Chem. 2009;17:6959-70.
44. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10:1236-42.
45. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19:2129-32.
46. Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther. 2012;91:134-42.
47. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. Nat Rev Drug Discov. 2010;9:761-2.
48. Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1Hisoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem. 2009;52:1522-4.
49. Crilly A, Robertson SE, Reilly JH, et al. Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Ann Rheum Dis. 2011;70:1130-7.
50. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12:R107.
51. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharideinduced signaling in mouse macrophages. J Immunol. 2005;175:1523-31.
52. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPSactivated TNF-alpha responses. Proc Natl Acad Sci USA. 2002;99:7628-33.
53. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842-55.
54. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17-26.
55. Kadoshima-Yamaoka K, Goto M, Murakawa M, et al. ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-alpha level and ameliorates skin edema in phorbol ester 12-Otetradecanoylphorbol-13-acetate-induced skin inflammation model in mice. Eur J Pharmacol. 2009;613:163-6.
56. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148:262-4.
57. Keravis T, Monneaux F, Yougbaré I, et al. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS ONE. 2012;7:e28899.
58. De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012;11:1224-6.
59. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49:2420-8.
60. Alase A, Wittmann M. Therapeutic strategies in allergic contact dermatitis. Recent Pat Inflamm Allergy Drug Discov. 2012;6:210-21.
61. Martin SF. Contact dermatitis: from pathomechanisms to immunotoxicology. Exp Dermatol. 2012;21:382-9.
62. Martin SF, Esser PR, Weber FC, et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy. 2011;66:1152-63.
63. Martin SF, Dudda JC, Bachtanian E, et al. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med. 2008;205:2151-62.
64. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148:890-7.
65. Volf EM, Au SC, Dumont N, Scheinman P. Gottlieb, A.B. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11:341-6.
66. Yamaki K, Li X, Uchida H, et al. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice. J Pharm Pharmacol. 2004;56:877-82.
67. Dehzad N, Bopp T, Reuter S, et al. Regulatory T cells more effectively suppress Th1-induced airway inflammation compared with Th2. J Immunol. 2011;186:2238-44.
68. Werfel T, Wittmann M. Regulatory role of T lymphocytes in atopic dermatitis. Chem Immunol Allergy. 2008;94:101-11.
69. Gottlieb AB, Strober B, Krueger JG, et al. An openlabel, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529-38.
70. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738-46.
71. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis. Arthritis Rheum. 2012;64:12.
72. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomised, controlled trial. Paper presented at: American College of Rheumatology, annual meeting, vol. 64 supplement. Arthritis and Rheumatism, Washington DC; 2012.
73. Taylor WJ, Zmierczak HG, Helliwell PS. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol. 2005;32:974-7.
74. Kingsley GH, Kowalczyk A, Taylor H, et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Rheumatology. 2012;51:1368-77.
75. Haibel H, Sieper J. Use of methotrexate in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010;28:S128-31.
76. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008;35:469-71.
77. Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8.
78. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
79. Mease PJ, Gladman DD, Ritchlin CT, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-89.